Geron Corporation (GERN)
NASDAQ: GERN · Real-Time Price · USD
3.490
-0.170 (-4.64%)
At close: Dec 20, 2024, 4:00 PM
3.520
+0.030 (0.86%)
After-hours: Dec 20, 2024, 5:13 PM EST
Company Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies.
It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.
The company was incorporated in 1990 and is headquartered in Foster City, California.
Geron Corporation
| Country | United States |
| Founded | 1990 |
| IPO Date | Jun 30, 1996 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 141 |
| CEO | John Scarlett |
Contact Details
Address: 919 East Hillsdale Boulevard, Suite 250 Foster City, California 94404 United States | |
| Phone | 650 473 7700 |
| Website | geron.com |
Stock Details
| Ticker Symbol | GERN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000886744 |
| CUSIP Number | 374163103 |
| ISIN Number | US3741631036 |
| Employer ID | 75-2287752 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. John A. Scarlett M.D. | Chairman of the Board, President and Chief Executive Officer |
| Michelle J. Robertson | Executive Vice President, Chief Financial Officer, Treasurer and Principal Financial and Accounting Officer |
| Dr. Andrew J. Grethlein Ph.D. | Executive Vice President and Chief Operating Officer |
| Scott Samuels | Executive Vice President, Chief Legal Officer and Secretary |
| Aron Feingold | Vice President of Investor Relations and Corporate Communications |
| Shannon Odam | Senior Vice President and Chief People Officer |
| Melissa A. Kelly Behrs | Executive Vice President of Business Operations and Chief Alliance Officer |
| Edward E. Koval | Executive Vice President and Chief Business Officer |
| Dr. Faye Feller M.D. | Executive Vice President and Chief Medical Officer |
| James Ziegler M.B.A. | Executive Vice President and Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Nov 7, 2024 | 8-K | Current Report |
| Aug 8, 2024 | 10-Q | Quarterly Report |
| Aug 8, 2024 | 8-K | Current Report |
| Jul 8, 2024 | 144 | Filing |
| Jun 10, 2024 | 144 | Filing |
| Jun 10, 2024 | 144 | Filing |